信息搜索
信息关键字：药
  

共有5246条记录

分页[首页] [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] [215] [216] [217] [218] [219] [220] [221] [222] [223] [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] [237] [238] [239] [240] [241] [242] [243] [244] [245] [246] [247] [248] [249] [250] [251] [252] [253] [254] [255] [256] [257] [258] [259] [260] [261] [262] [263]

·2022年1月湖北新三板企业市值TOP100：宏源药业位居第一市值超38亿元2022-2-6 17:12:14
·东北制药净利润预增553%-879%?业绩进入新增长期2022-2-5 10:00:24
·32家中药企业业绩预告：康美药业扭亏为盈太安堂预亏近8亿2022-2-5 9:13:59
·新冠口服药能增厚多少营收？默沙东：一年50至60亿美元2022-2-4 7:28:53
·中成药集采开始了首次省际联采111个产品拟中选2022-2-3 9:38:34
·1月股基红黑榜：港股主题翻身多只医药健康类跌幅近20%2022-2-3 8:00:06
·美股港股暴动互联网、生物医药两大中概股强力反弹A股开门红吹响集结号？2022-2-1 17:41:22
·北向资金1月扫货167亿！64亿加仓“银行茅”减仓“药茅”“宁王”2022-1-31 17:46:19
·55家化药制剂企业去年业绩预告：19家预亏12家扭亏为盈2022-1-31 15:27:03
·科创板生物医药2021年报预告扫描：体外诊断成最赚钱赛道创新药企最舍得研发2022-1-31 13:05:36
·恒指高开0.31%零售、制药等板块领涨2022-1-31 12:06:53
·九典制药扣非净利润预增超1.6倍研发投入增五成2022-1-31 10:13:32
·生物医药企业开年IPO继续“破发”到底如何看待创新药在资本市场遇冷？2022-1-31 7:27:06
·科兴：注销房地产项目公司专注生物医药领域2022-1-30 18:07:52
·科兴中维：公司现在没有、将来也不会进入房地产行业坚定聚焦生物医药领域2022-1-30 18:03:17
·景峰医药2021年预计亏损3600万-7200万同比亏损减少各项成本费用下降2022-1-30 14:20:33
·亿帆医药2021年预计净利2.2亿-3.2亿同比下降77%-67%原料药业务主要产品价格下降2022-1-30 13:16:49
·尔康制药2021年预计亏损6.5亿-8.2亿同比由盈转亏淀粉囊国内市场推广不达预期?2022-1-29 16:22:23
·国家联采办取消贵州圣济堂制药有限公司格列美脲片中选资格并将该企业列入违规名单2022-1-29 16:17:58
·西陇科学：公司不涉及新冠药物的研发业务3HP产品收入占比较小2022-1-29 4:48:20

分页[首页] [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] [215] [216] [217] [218] [219] [220] [221] [222] [223] [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] [237] [238] [239] [240] [241] [242] [243] [244] [245] [246] [247] [248] [249] [250] [251] [252] [253] [254] [255] [256] [257] [258] [259] [260] [261] [262] [263]